Kornimate/medical-research-clean huggingface dataset:
resuscitative endocrinology: single-dose clinical uses for estrogen-traumatic hemorrhagic shock (rescue - shock)

Conditions: Hemorrhagic Shock

Summary: based on encouraging results from animal studies, the investigators hypothesize that early administration of iv premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.

annually in the united states, approximately 30 million people require treatment for traumatic injuries in emergency departments. two million of these patients require hospitalization, with several hundred thousand ultimately dying, often due to extreme blood loss. importantly, these traumatic injuries are the leading cause of death and disability for children and young adults under the age of 44, with the total cost of trauma in the u.s. approaching $260 billion each year. despite advances in pre-hospital care, early resuscitation, surgical interventions and intensive care monitoring aimed at the primary traumatic injury, many survivors never recover. a significant cause of this mortality and morbidity is thought due to potentially preventable secondary injury, namely oxidant injury, inflammation, and apoptosis beginning in the first few hours after the severe traumatic event. in spite of the current bleak outlook for many of these patients, a series of animal investigations have uncovered a promising solution to the problem of the secondary injury seen in hemorrhagic shock and other similar processes, namely the early administration of estrogen, a strong anti-oxidant, anti-inflammatory and anti-apoptotic compound. based on encouraging results from animal studies, the investigators hypothesize that early administration of iv premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.

Eligibility criteria:
inclusion criteria: 1. age≥ 18 yrs or \< 50 yrs 2. blunt or penetrating trauma leading to presumed hemorrhagic shock 3. pre-hospital or ed systolic blood pressure \< 90 4. receiving medical treatment in the emergency department (ed) of parkland hospital or baylor university medical center emergency department, level i trauma centers in dallas, texas exclusion criteria: 1. those who would receive the study drug \> 120 minutes after the traumatic event 2. time of injury is unknown 3. known indication for iv estrogen 4. known contraindication for estrogen 5. estimated age \ 50 years 6. cardiopulmonary resuscitation (cpr) prior to randomization 7. known incarceration 8. severe hypothermia (suspected t \< 28° c) 9. drowning or asphyxia due to hanging 10. burns total body surface area (tbsa) \> 20% 11. isolated penetrating injury to the head 12. known inclusion in another interventional trial related to this traumatic event prior to randomization 13. known legal do not resuscitate (dnr) orders in place prior to randomization 14. recognized spinal cord injury prior to study drug administration
commuter air pollution intervention study

Conditions: Cognitive Function; Cardiopulmonary Function; Saliva Stress Hormones; Air Pollution Exposure; Lung Inflammation

Summary: traffic related air pollution is a well-recognised and much studied contributor to smog and is linked to a number of adverse health outcomes. although traffic pollutants can travel long distances, exposure to the highest levels of the raw emissions can occur closest to the source; e.g. in a car in dense traffic conditions. time spent in-vehicle may contribute up to half of commuters' daily exposure to certain air pollutants. most new cars now have or allow for a cabin air filter, but it is not known how well cabin air filtration can reduce exposure to traffic-related air pollution. this intervention study will measure commuters' exposure to air pollutants in rush hour traffic. it will evaluate the impact of this exposure on stress hormones in saliva, and short term cardiopulmonary health indicators such as blood pressure, heart rate variability and respiratory inflammation. it will also look at effects on cognition (mental processing and judgement) in this real world environment where any deficit could be important to safety. in addition, the study will examine whether cabin air filtration can reduce the exposure to traffic related air pollutants and result in improvements in short term cardiopulmonary and cognitive function. this research will contribute to our understanding of how this environment contributes to canadians' overall air pollution exposure as well as the potential health impacts. it will also test a potentially valuable and economical means of reducing exposure to traffic related air pollution in a commuting environment. the study may also guide the future implementation of the use of cabin filters as an exposure reduction intervention. overall project objectives: can cabin air filtration effectively reduce exposure to traffic related air pollution? does commuter exposure to air pollution affect short term stress, and cardiopulmonary and cognitive function? can cabin air filtration mitigate the health effects of commuters' exposure to air pollution?


Eligibility criteria:
inclusion criteria: * healthy individuals; * non-smoking. exclusion criteria: * smokers; * living in a smoking household; * currently experiencing seasonal allergies; * suffering from heart rhythm problems or heart conditions; * regularly taking corticosteroid medication; * pregnant or breastfeeding; * allergic to latex; * sensitivity to adhesives

Keywords: cabin air filtration particulate matter commuter exposure traffic related air pollution
structured data collection of patients undergoing liver transplantation and evaluated for bone mineral metabolism

Conditions: Osteoporosis; Liver Transplant

Summary: observational cohort study offered consecutively to every liver transplant patient who arrives for the first endocrinology visit or returns for follow-up visit for bone metabolism assessment.

the retrospective and prospective single-center observational cohort study will be offered consecutively to every liver transplant patient who arrives for the first endocrinology visit or returns for follow-up visit for bone metabolism assessment at uo endocrinology of policlinico s. orsola-malpighi.

Eligibility criteria:
inclusion criteria: * age \>18 years * patients undergoing liver transplantation for any cause. * performance of bone densitometry * performance of examinations pertaining to mineral metabolism * obtaining informed consent exclusion criteria: * none
a clinical study of gp73 as a hepatocellular carcinoma (hcc) tumor mark

Conditions: Hepatocellular Carcinoma

Summary: the aims of this study were divided into three parts: 1. to evaluate the sensitivity and specificity of gp73 for the diagnosis of hepatitis b related hcc. established the standard of gp73 in normal people. 2. to definitude the connections between the gp73 level and various diseases. 3. to find the relations of hcc metastasis and recurrence. study design: 1. collectivity type: prospective，randomized, controlled, multi-central clinical study. 2. patients: the subjects were from different hospitals including: peking union medical college hospital (pumch), the cancer hospital of peking union medical college (pumc), qidong cancer institute, and department of surgery university of chicago from november of 2007 till the end of this study. study arrangement: this study was consisted of three parts: 1. established the standard of normal people and test the sensitivity and specificity of hcc patients. the samples were acquired from health screen center and department of liver surgery of pumch, the cancer hospital of pumc and qidong cancer institute. 2. extend the study bound, including the hepatitis b virus (hbv) and hepatitis c virus (hcv) carriers. the hbv (+) samples were come from chinese hospitals and institutions. the hcv (+) samples were provide by the department of surgery university of chicago. 3. research the relations of serum gp73 level and the other diseases, such as other malignant liver tumors, liver metastatic tumors, liver benign tumor, hcc recurrence following surgery etc.


Eligibility criteria:
inclusion criteria: * a group of patients with no history of liver disease, alcohol consumption less than 40g a week, and no risk factors for viral hepatitis were enrolled from the general internal medicine clinics. all subjects in this control group were documented to have normal liver biochemistry. * consecutive patients with hcc and patients with hbv \& hcv that were age, gender, and race/ethnicity matched to the hcc patients were enrolled from the liver clinic during this period. the diagnosis of hcc was made by histopathology, and if histopathology was not available by two imaging modalities (ultrasound \[us\], magnetic resonance imaging \[mri\], or computed tomography) showing a vascular enhancing mass \>2cm. hbv infection status was based on hepatitis b surface antigen (hbsag). hcv infection status was based on serum hcv antibody and hcv-rna positive.

Keywords: hepatocellular carcinoma
effectiveness of "medisinstart"

Conditions: Cardiovascular Diseases

Summary: "medisinstart" is a new service developed for use in norwegian pharmacies. it is intended for patients that are about to start a new medicine for a chronic or long-term condition. it is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. the service consists of two follow-up consultations with a pharmacist. the first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine. the main purpose of this study is to investigate whether "medisinstart" increases patients' adherence to the prescribed medication. patients' beliefs about their medicines and their motivation for adherence will also be examined. the study also aims at revealing if "medisinstart" has additional benefits for the patient, the society and the pharmacies.


Eligibility criteria:
inclusion criteria: first time prescription for a drug belonging to one of the following groups (atc-code): * dabigatran etexilate (b01ae07) * rivaroxaban (b01af01) * apixaban (b01af02) * beta blocking agents (c07) * calcium channel blockers (c08) * agents acting on the renin-angiotensin system (c09) * hmg coa reductase inhibitors (statins) (c10aa) exclusion criteria: * prior use (within the last 3 years) of the drug in question independent of strength, dose and formulation

Keywords: adherence morisky medication adherence scale beliefs about medicines questionnaire medication possession ratio medication-related problems pharmacist pharmacist intervention pharmacy pharmacy service pharmacy practice hypertension antihypertensive agents anticoagulants statins dyslipidemia
a study to assess the efficacy and safety of tanfanercept (hl036) ophthalmic solution in participants with dry eye

Conditions: Dry Eye

Summary: the objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.


Eligibility criteria:
inclusion criteria: * have a participant-reported history of dry eye for at least 6 months prior to visit 1 * have a history of use or desire to use eye drops for dry eye symptoms within 6 months of visit 1 * have a best-corrected visual acuity (bcva) of 0.7 minimum angle of resolution (logmar) or better (snellen equivalent score of 20/100 or better) in each eye at visit 1 * report a score of ≥ 2 according to the ora calibra® ocular discomfort \& 4-symptom questionnaire in at least one of the dry eye symptoms at visits 1 and 2 * have a schirmer's test score of ≤ 10 millimeter (mm) and ≥ 1 mm in at least one eye at visits 1 and 2 * have a corneal fluorescein staining score ≥ 2 according to the ora calibra® corneal and conjunctival staining scale for grading of fluorescein staining in at least 1 of the corneal regions (inferior, superior, or central) in at least 1 eye at visits 1 and 2 * have a conjunctival redness score ≥ 1 according to the ora calibra® conjunctival redness for dry eye scale in at least 1 eye at visits 1 and 2 exclusion criteria: * have any clinically significant slit lamp findings at visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters * be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at visit 1 * have worn contact lenses within 7 days of visit 1 or anticipate using contact lenses during the study * have previously had laser-assisted in situ keratomileusis (lasik) surgery within the last 12 months * have used any cyclosporine-containing drops (such as restasis®, cequa®), or lifitegrast ophthalmic solution (xiidra®) within 60 days of visit 1 * have any previous experience using tnf inhibitor ophthalmic solutions, such tanfanercept ophthalmic solution * be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter (otc) solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study) * be a woman who is pregnant, nursing or planning a pregnancy
infusion of cell populations from unlicensed umbilical cord blood units

Conditions: Lymphatic Diseases; Hematopoietic Malignancy

Summary: for the next 5-10 years or possibly longer, a high proportion of the cord blood banks (cbb) inventory worldwide will be composed of unlicensed umbilical cord blood (ucb) units. while food and drug administration (fda)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed ucb units.

patients will receive intravenous hydration, acetaminophen and diphenhydramine hydrochloride (or appropriate alternative regimen) approximately 30 minutes prior to ucb infusion with doses adjusted for subject age and weight unless otherwise specified in the specific treatment protocol. additional treatments will vary with the specific use of the ucb cells as specified in institutional review board (irb)-approved disease-specific protocols at the university of minnesota.

Eligibility criteria:
inclusion criteria: to be eligible for an unlicensed umbilical cord blood (ucb) unit, the subject must meet each of the eligibility criteria listed below: * subjects with any diagnosis for which there is an institutional review board (irb) approved treatment protocol that requires ucb as a source of hematopoietic stem cells for lympho-hematopoietic reconstitution after myeloablative or non myeloablative conditioning. * subject (or parent/guardian) must provide written informed consent for the use of unlicensed ucb units with co-enrollment onto a university of minnesota irb-approved clinical trial that details the disease specific treatment plan that prescribes the use of ucb as source of cells * subject has an unlicensed ucb unit that meets required cell dose and hla matching criteria (as defined in the primary treatment protocol) that is considered negative for tested blood-borne pathogens and also lack an 'equivalent', licensed ucb unit from a university of minnesota approved cord blood bank exclusion criteria: * exclusion criteria are specified in the treatment protocol according to indication.

Keywords: umbilical cord blood
diaphragm function and diver endurance

Conditions: Respiratory Muscles

Summary: this project will test the following hypotheses: 1. training of the inspiratory muscles increases underwater endurance and reduces hypercapnia in divers. 2. inspiratory muscle training while breathing low concentration carbon monoxide (200 ppm) for 30 minutes daily improves diaphragm performance to a greater degree than the same training breathing air. 3. inspiratory muscle training increases hypercapnia ventilatory response (gain) in those individuals with a low gain. 4. variability in oxygen (o2) and carbon dioxide (co2) permeability of erythrocyte membranes is a determining factor in underwater exercise performance.

the aims of this project are to: (1) test a method that could increase personal endurance and reduce excessive rise in blood carbon dioxide during underwater exercise in divers; and (2) understand the mechanisms by which red blood cells transport oxygen and carbon dioxide and their possible effects on exercise capacity. during underwater exercise, personal endurance capacity and elevated blood pco2 are key parameters that affect a diver's safety and performance. unlike exercise on dry land, hypercapnia often occurs during dives and can impair cognitive function and predispose the diver to central nervous system (cns) oxygen toxicity and convulsions underwater. some people intrinsically have low ventilatory chemosensitivity, and are more likely to develop hypercapnia during a dive. lack of stamina may also be a mission-critical variable, and both endurance and the ability to control blood carbon dioxide depend on the respiratory muscle (mainly diaphragm) function, for which endurance capacity is related to mitochondrial number. previous studies from our lab have demonstrated increased mitochondrial biogenesis with training while breathing a low, sub-toxic (200 ppm) level of carbon monoxide. in this study we will test the effect of daily respiratory muscle training with and without added carbon monoxide on respiratory muscle power, diaphragm thickness, respiratory muscle endurance and exercise endurance during a subsequent dive to 50 feet of sea water. arterial pco2 and lactic acid levels will be measured during exercise tests before and after training. transport of o2 and co2 through erythrocyte cell membranes occurs mostly through channels. erythrocytes from volunteers in this study will be tested for o2 and co2 permeability, and to correlate gas transport efficiency with exercise performance and blood pco2.

Eligibility criteria:
inclusion criteria: * normal volunteers * non-smokers * range of hypercapnic ventilatory responses * vo2peak ≥35 ml.kg-1.min-1 (males) * ≥30 ml.kg-1.min-1 (females) exclusion criteria: * pregnancy * cardiorespiratory disease, including hypertension * neuromuscular disease * anemia * hemoglobinopathy, including sickle cell disease and trait

Keywords: control of breathing diaphragm function gas channels blood gases
the actonheart study: design of a randomized controlled clinical trial of acceptance and commitment therapy for cardiac patients

Conditions: Cardiovascular Diseases

Summary: the study will determine whether a brief intervention program based on acceptance and commitment therapy can be effective for the reduction of modifiable risk factors and improvement of psychological well-being in patients referred to cardiac rehabilitation

the acceptance and commitment therapy is a mindfulness-based intervention which efficacy has been proven in the treatment of depression and anxiety, in stress reduction and in the modification of health- related behaviors in patients with several physical conditions. the application of an acceptance-based program in cardiac patients has revealed high treatment satisfaction and initial evidences of effectiveness in increasing heart-healthy behaviour. the purpose of the trial is to evaluate the efficacy of a brief group-administered program based on acceptance and commitment therapy in improving patients' ability to address modifiable multiple cardiovascular risk factors and overall psychological well-being, compared with the usual care.

Eligibility criteria:
inclusion criteria: * having a current diagnosis of ischemic heart disease (ihd) * being affected by major modifiable cardiovascular risk factors that will be assessed through the interheart modifiable risk score. only subjects with a full score \>9 will be included in the study. * between the ages of 18 and 70 years * fluency in spoken and written italian language * expression of written informed consent. exclusion criteria: * cognitive impairment * severe psychiatric disorders according to diagnostic and statistical manual-iv tr criteria (apa, 2000).

Keywords: acceptance and commitment therapy cardiac rehabilitation
18fdg pet textural indices in adrenal lesion

Conditions: Adrenal Tumor

Summary: tumors are characterized by a great heterogeneity. characterizing this intra-tumor heterogeneity is a major challenge in oncology to improve the therapeutic management and move towards personalized medicine adapted to each patient. however, intra-tumor heterogeneity remains rarely used for diagnostic purposes the discovery of an adrenal mass can occur in different circumstances. detection of an adrenal mass can be done in a context of secreting syndrome, in the assessment of an extra-adrenal neoplasia or fortuitously when performing an imaging for another reason. the etiologies are numerous (cortical tumors, medullary tumors, metastatic lesion of a extra-adrenal neoplasia, others). the adrenal masses can be divided into two categories, depending on whether they are hyperfunctional or not. in patients without an oncological history, an adrenal mass discovered is most often a benign adenoma, but requires an endocrine assessment. in patients with known primary cancer, approximately 30% of the adrenal masses are malignant. in all cases, the diagnostic procedure includes an imaging assessment to characterize the lesion and an endocrine assessment. ct scan performed without and after intravenous iodinated contrast agent injection is the first-line examination to assess an adrenal mass. 18f-fdg-pet may be indicated as second-line for characterizing an adrenal mass. adrenal tumor suvmax (standard uptake value) and adrenal tumor suvmax / liver suvmax ratio are routinely used to determine the malignancy of a lesion. although very useful for assessing the glucose metabolism of a given lesion, these parameters do not allow assessing the heterogeneity of tumor uptake. the texture analysis corresponds to an analysis of the spatial distribution of fdg uptake, and allows, by the calculation of many indices, an evaluation of the heterogeneity of the tumors. the hypothesis of our study is that the texture parameters could have an additional diagnostic value to improve the performance of conventional quantitative parameters to determine the malignancy of a lesion. the objective of this study is to investigate the diagnostic value of texture indices in a large cohort of patients presenting an adrenal lesion


Eligibility criteria:
inclusion criteria: * having benefited from a 18-fdg pet-ct scan in the nuclear medicine department of university hospital of brest * addressed in the context of an assessment of an adrenal lesion, in the evaluation of an extra-adrenal neoplasia or other motive * presenting an adrenal lesion * from june 29, 2012 to june 30, 2017 exclusion criteria: * patients followed in another center than the university hospital of brest * lesions of undetermined nature * diagnosis of benignity or malignancy not confirmed by anatomopathology. * patient having expressed his opposition to the use of his medical data

Keywords: positron emission tomography texture indices diagnostic performance